Patients receiving Pola-R-CHP were found to be more likely to be male (58% vs 54%), younger (mean age, 75.0 vs 77.5 years), ...
A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...
Based on the primary PFS analysis of EMBER-3, the FDA approved single-agent imlunestrant in September 2025 for the treatment of patients with ER+/HER2– ESR1 m advanced breast cancer with disease ...
The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...
Infection management in hematologic malignancies is critical due to higher mortality risks, necessitating improved communication between patients and providers. Remote therapeutic monitoring platforms ...
Long-term follow-up in the PALLAS study showed no overall survival benefit with palbociclib plus endocrine therapy compared to endocrine therapy alone in hormone receptor-positive, HER2-negative ...
Hormone replacement therapy (HRT) does not increase breast cancer risk in BRCA1/BRCA2 carriers, with estrogen-alone formulations showing a lower risk. The study used a matched-pair design to control ...
Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial reported median PFS of 8.3 months ...
Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback